MX2013013111A - Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma. - Google Patents
Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.Info
- Publication number
- MX2013013111A MX2013013111A MX2013013111A MX2013013111A MX2013013111A MX 2013013111 A MX2013013111 A MX 2013013111A MX 2013013111 A MX2013013111 A MX 2013013111A MX 2013013111 A MX2013013111 A MX 2013013111A MX 2013013111 A MX2013013111 A MX 2013013111A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen presenting
- methods
- multiple antigen
- immunogenic composition
- antigens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Las presentes modalidades proporcionan un sistema que presenta antígeno múltiple inmunogénico que comprende un polímero al cual se asocian antígenos mediante moléculas de afinidad complementarias. Por ejemplo, el polímero puede ser un polisacárido, o polisacárido antigénico, al cual se enlazan indirectamente antígenos de proteína o de péptido de los mismos o diferentes patógenos. Las presentes composiciones inmunogénicas pueden inducir respuestas inmunes tanto humorales como celulares a uno o múltiples antígenos al mismo tiempo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161484934P | 2011-05-11 | 2011-05-11 | |
US201261608168P | 2012-03-08 | 2012-03-08 | |
US201261609974P | 2012-03-13 | 2012-03-13 | |
PCT/US2012/037412 WO2012155007A1 (en) | 2011-05-11 | 2012-05-11 | Multiple antigen presenting immunogenic composition, and methods and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013013111A true MX2013013111A (es) | 2015-03-04 |
Family
ID=47139675
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013013111A MX2013013111A (es) | 2011-05-11 | 2012-05-11 | Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma. |
MX2013013112A MX2013013112A (es) | 2011-05-11 | 2012-05-11 | Proteina que enlaza biotina modificada, proteinas de fusion de la misma y aplicaciones. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013013112A MX2013013112A (es) | 2011-05-11 | 2012-05-11 | Proteina que enlaza biotina modificada, proteinas de fusion de la misma y aplicaciones. |
Country Status (13)
Country | Link |
---|---|
US (7) | US10766932B2 (es) |
EP (4) | EP3881836A1 (es) |
JP (7) | JP6366501B2 (es) |
KR (4) | KR20140146993A (es) |
CN (4) | CN103732222B (es) |
AU (2) | AU2012253327B2 (es) |
BR (2) | BR112013028892B1 (es) |
CA (2) | CA2835628C (es) |
ES (2) | ES2864765T3 (es) |
MX (2) | MX2013013111A (es) |
RU (2) | RU2632651C2 (es) |
WO (2) | WO2012155007A1 (es) |
ZA (2) | ZA201308461B (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE503837T1 (de) * | 2000-02-28 | 2011-04-15 | Novartis Vaccines & Diagnostic | Hybride expression neisserscher proteine |
US9125863B2 (en) * | 2008-05-22 | 2015-09-08 | Children's Medical Center Corporation | Synergistic immunogenic fusion protein-polysaccharide conjugate |
KR20140146993A (ko) * | 2011-05-11 | 2014-12-29 | 칠드런'즈 메디컬 센터 코포레이션 | 다항원 제시 면역성 조성물, 및 그 방법 및 용도 |
US10500283B2 (en) * | 2011-05-30 | 2019-12-10 | National Institute Of Immunology | Vaccine composition capable of inducing memory antibody response from single point immunization |
US9265819B2 (en) * | 2011-09-21 | 2016-02-23 | St. Jude Children's Research Hospital | Live, attenuated Streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease |
US9274430B2 (en) | 2012-10-10 | 2016-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and devices for molecule sensing and method of manufacturing thereof |
CA2900008A1 (en) * | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
US9981997B2 (en) | 2013-10-31 | 2018-05-29 | Arizona Board Of Regents On Behalf Of Arizona State University | Chemical reagents for attaching affinity molecules on surfaces |
WO2016044588A1 (en) * | 2014-09-19 | 2016-03-24 | The Regents Of The University Of Michigan | Staphylococcus aureus materials and methods |
CN104548101B (zh) * | 2015-01-31 | 2017-02-22 | 广东海大畜牧兽医研究院有限公司 | 一种诱导哺乳动物乳腺黏膜产生IgA的免疫增强剂及其制备方法和应用 |
CN105646681B (zh) * | 2016-01-21 | 2021-07-16 | 浙江海隆生物科技有限公司 | 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用 |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
JP2019524639A (ja) * | 2016-05-04 | 2019-09-05 | ザ チルドレンズ メディカル センター コーポレーション | アビジン様タンパク質およびそれらの融合タンパク質を精製する方法 |
US10751398B2 (en) * | 2016-10-07 | 2020-08-25 | Loyola University Chicago | Inflammasome activators and methods of use to treat tumors |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
US20180161433A1 (en) * | 2017-03-22 | 2018-06-14 | Timothy Andrew Erickson | Size tunable microbial mimetics for immunotherapy of thyroid carcinomas and solid tumors |
WO2018183475A1 (en) * | 2017-03-28 | 2018-10-04 | Children's Medical Center Corporation | A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof |
KR20200018787A (ko) * | 2017-05-22 | 2020-02-20 | 더 칠드런스 메디칼 센터 코포레이션 | 마이코박테리움 투버큘로시스에 대한 혼합 백신 |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
BR112019026192B1 (pt) | 2017-06-10 | 2022-05-10 | Inventprise, Llc | Vacinas de conjugado multivalente com polissacarídeos de conjugado bivalente ou multivalente que fornecem imunogenicidade e avidez melhoradas |
EP3641828B1 (en) | 2017-06-23 | 2023-11-22 | Affinivax, Inc. | Immunogenic compositions |
US20200179491A1 (en) * | 2017-07-19 | 2020-06-11 | Children's Medical Center Corporation | Compositions and methods for treating diseases associated with an imprinting defect |
US11541110B2 (en) | 2017-10-13 | 2023-01-03 | The Research Foundation For The State University Of New York | Comprehensive vaccine design for commensal disease progression |
CN108339115B (zh) * | 2018-05-11 | 2020-07-10 | 武汉博沃生物科技有限公司 | 使用重组载体蛋白的肺炎球菌联合疫苗及其制备方法 |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
BR112021004193A2 (pt) * | 2018-09-12 | 2021-05-25 | Affinivax, Inc. | vacinas pneumocócicas multivalentes |
BR112021004185A2 (pt) * | 2018-09-12 | 2021-05-25 | The Children's Medical Center Corporation | vacinas de proteína de fusão pneumocócica |
US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
CN109400704B (zh) * | 2018-11-14 | 2020-07-21 | 珠海泰诺麦博生物技术有限公司 | 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用 |
EP3935159A1 (en) | 2019-03-08 | 2022-01-12 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
WO2020223240A1 (en) * | 2019-04-29 | 2020-11-05 | The Broad Institute, Inc. | Affinity-based multiplexing for live-cell monitoring of complex cell populations |
WO2020252405A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
CN111518822B (zh) * | 2019-07-02 | 2022-08-09 | 江南大学 | 一种硫酸软骨素abc裂解酶突变体及其分泌表达的方法 |
JP2021029171A (ja) * | 2019-08-23 | 2021-03-01 | 国立大学法人東京農工大学 | ブレビバチルス菌を用いた表層提示法 |
US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
EP4054624A4 (en) * | 2019-11-05 | 2023-12-27 | Beth Israel Deaconess Medical Center, Inc. | MYCOBACTERIAL COMPOSITIONS AND BIOMARRKERS FOR USE IN TREATMENT AND MONITORING THERAPEUTIC RESPONSE |
US20230340402A1 (en) * | 2019-12-27 | 2023-10-26 | Amolifescience Co., Ltd. | Cell culture substrate and manufacturing method thereof |
CN115151631A (zh) * | 2019-12-27 | 2022-10-04 | 阿莫生命科学有限公司 | 细胞培养基材及其制备方法 |
CN116113644A (zh) * | 2020-09-14 | 2023-05-12 | 神州细胞工程有限公司 | 通过糖-冠状病毒rbd抗原缀合物提高免疫原性的方法 |
WO2023081674A1 (en) | 2021-11-02 | 2023-05-11 | Arvada Therapeutics, Inc. | Dsg2 compositions and methods |
WO2022216734A1 (en) * | 2021-04-06 | 2022-10-13 | The Board Of Trustees Of The University Of Illinois | Multivalent cholera multiepitope fusion antigen (mefa) and methods of use |
US20230233667A1 (en) | 2021-09-08 | 2023-07-27 | Affinivax, Inc. | Coronavirus vaccine |
AU2022342080A1 (en) | 2021-09-09 | 2024-03-28 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
WO2023069278A1 (en) * | 2021-10-20 | 2023-04-27 | Fina Biosolutions, Llc | Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines |
WO2023102359A1 (en) * | 2021-12-02 | 2023-06-08 | The Children's Medical Center Corporation | A maps vaccine targeting salmonella enterica serovars |
WO2023192997A2 (en) * | 2022-03-31 | 2023-10-05 | The Children's Medical Center Corporation | Immunogenic compositions for b-cell recall response to a polysaccharide antigen |
CN115819624B (zh) * | 2022-12-16 | 2023-12-15 | 深圳华腾生物医药科技有限公司 | 一种重组融合蛋白及其制备方法和应用 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US244420A (en) | 1881-07-19 | Stove pipe threadeb and beader | ||
US3887699A (en) | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4673641A (en) | 1982-12-16 | 1987-06-16 | Molecular Genetics Research And Development Limited Partnership | Co-aggregate purification of proteins |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
DE3413608A1 (de) | 1984-04-11 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung |
US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
NZ224422A (en) | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5179007A (en) | 1989-07-07 | 1993-01-12 | The Texas A & M University System | Method and vector for the purification of foreign proteins |
FR2664905B1 (fr) | 1990-07-18 | 1994-08-12 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
US5516657A (en) | 1992-05-11 | 1996-05-14 | Cambridge Biotech Corporation | Baculovirus vectors for expression of secretory and membrane-bound proteins |
US5390111A (en) | 1993-11-12 | 1995-02-14 | General Electric Company | Method and system for processing cone beam data for reconstructing free of boundary-induced artifacts a three dimensional computerized tomography image |
AU1377395A (en) | 1993-12-23 | 1995-07-10 | University Technologies International Inc. | Methods of expressing proteins in insect cells and methods of killing insects |
IL112372A (en) | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
DE69628418T2 (de) | 1995-03-22 | 2004-04-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden |
SE9603413L (sv) | 1996-09-19 | 1998-02-09 | Atlas Copco Rocktech Ab | Kopplingsstycke för användning vid samtidig jord- och/eller bergborrning med en övre rotationsslaganordning och en undre slaganordning |
EP1770164B1 (en) | 1996-10-31 | 2010-09-01 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
DE69826851T2 (de) | 1997-04-24 | 2005-02-10 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen |
US7060458B1 (en) * | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
WO1999012416A1 (en) | 1997-09-09 | 1999-03-18 | The Trustees Of Columbia University In The City Of New York | T-independent conjugate-vaccines |
SE9900496D0 (sv) | 1999-02-12 | 1999-02-12 | Pharmatrix Ab | Vaccine formulation |
US6398774B1 (en) | 1999-09-29 | 2002-06-04 | Heska Corporation | Intranasal delivery system |
US8246945B2 (en) | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
US6919187B2 (en) | 2000-04-21 | 2005-07-19 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
DK2116257T3 (da) | 2000-08-09 | 2013-02-04 | Alk Abello As | Parenterale vaccineformuleringer og anvendelser deraf |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
AU2003239744B2 (en) | 2002-05-14 | 2008-07-03 | Novartis Vaccines And Diagnostics S.R.L. | Mucosal combination vaccines for bacterial meningitis |
CA2519511A1 (en) * | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
EP2336357A1 (en) | 2003-04-15 | 2011-06-22 | Intercell AG | S. pneumoniae antigens |
EP2301571A1 (en) | 2003-05-07 | 2011-03-30 | Sanofi Pasteur Inc. | Tetravalent meningococcal vaccine with enhanced immunogenicity |
EP1670509A4 (en) * | 2003-09-03 | 2007-10-31 | Dendritherapeutics Inc | MULTIPLEX VACCINES |
US7556814B2 (en) | 2003-10-23 | 2009-07-07 | Karp Nelson M | Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane |
AU2004314347B2 (en) | 2003-12-24 | 2011-05-19 | Aduro Biotech, Inc. | Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof |
WO2005103073A2 (en) * | 2004-04-27 | 2005-11-03 | Intercell Ag | Td antigens |
GB0410220D0 (en) * | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
WO2006017929A1 (en) | 2004-08-18 | 2006-02-23 | Governors Of The University Of Alberta | Protein production method utilizing yebf |
FI20041396A0 (fi) * | 2004-10-29 | 2004-10-29 | Vesa Pekka Hytoenen | Uudet mikrobiavidiinit |
EP1812055A4 (en) | 2004-11-11 | 2008-09-03 | Univ Queensland | CHLAMYDIEN-ANTIGENE AND ITS USES |
GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
EP1855717A4 (en) | 2005-02-11 | 2009-12-23 | Ace Biosciences As | ON THE SURFACE STREPTOCOCCUS PNEUMONIAE POLYPEPTIDE |
US20090148894A1 (en) | 2005-08-15 | 2009-06-11 | Broedel Sheldon E | Methods for optimizing the secretion of protein in prokaryotes |
JP5135220B2 (ja) | 2005-09-01 | 2013-02-06 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 血清群c髄膜炎菌を含む複数ワクチン接種 |
EP1976565A2 (en) * | 2005-12-08 | 2008-10-08 | University of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
WO2007081583A2 (en) * | 2006-01-04 | 2007-07-19 | Children's Medical Center Corporation | Anti-pneumococcal preparations and methods of use |
US7943133B2 (en) | 2006-02-02 | 2011-05-17 | Boston Biocom Llc | Mesothelin antibody protein fusions and methods of use |
US20080032340A1 (en) | 2006-06-09 | 2008-02-07 | University Of Arizona | Peptide motifs for binding avidin or neutravidin |
WO2007149982A2 (en) * | 2006-06-22 | 2007-12-27 | The Brigham And Women's Hospital, Inc. | Diagnosis of autoimmune disease |
US8318912B2 (en) | 2006-06-23 | 2012-11-27 | Augmenta Biologicals, Llc | Targeted immune conjugate comprising an antibody to glycophorin A and a M2e peptide |
US7452985B2 (en) | 2006-08-17 | 2008-11-18 | Visgeneer, Inc. | Human Ron-related gene variant associated with cancers |
EP2104512A2 (en) * | 2006-12-21 | 2009-09-30 | Emergent Product Development UK Limited | Streptococcus proteins, and their use in vaccination |
CN100579152C (zh) | 2007-01-29 | 2010-01-06 | 华为技术有限公司 | 一种播放集团彩铃的方法、系统及装置 |
EP2468869B1 (en) | 2007-01-31 | 2015-03-18 | Pfenex Inc. | Bacterial leader sequences for increased expression |
EP2147015A4 (en) | 2007-04-13 | 2011-01-26 | Univ Oklahoma State | CHOLESTEROL DEPENDENT CYTOLYSIN MUTANTS AND USES THEREOF |
RS54349B1 (en) | 2007-06-26 | 2016-02-29 | Glaxosmithkline Biologicals S.A. | VACCINE CONTAINING STREPTOCOCCUS PNEUMONIAE Capsular POLYSACCHARIDE CONJUGATES |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
JP2010535504A (ja) | 2007-08-03 | 2010-11-25 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | クラミジア抗原 |
US20100168392A1 (en) | 2007-08-10 | 2010-07-01 | Wacker Chemie Ag | Expression of full length igg and secretion into the culture medium of prokaryotic cells |
KR101661946B1 (ko) | 2007-08-31 | 2016-10-05 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
AU2009329782B2 (en) | 2008-12-24 | 2016-01-28 | The Kingdom Of The Netherlands, Represented By The Minister Of Health, Welfare And Sport, On Behalf Of The Minister, The National Institute Of Public Health And The Environment | Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides |
EP2208787A1 (en) * | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
SG10201403702SA (en) | 2009-06-29 | 2014-09-26 | Genocea Biosciences Inc | Vaccines and compositions against streptococcus pneumoniae |
CN101797381B (zh) | 2010-01-29 | 2012-05-23 | 中国人民解放军第三军医大学 | 乙肝病毒抗原与路易斯寡糖的复合物及其制备方法和应用 |
WO2011137354A2 (en) | 2010-04-30 | 2011-11-03 | Augmenta Biologicals, Llc | Delivery proteins |
KR20140146993A (ko) | 2011-05-11 | 2014-12-29 | 칠드런'즈 메디컬 센터 코포레이션 | 다항원 제시 면역성 조성물, 및 그 방법 및 용도 |
WO2014018904A1 (en) | 2012-07-26 | 2014-01-30 | Genocea Biosciences, Inc. | Fused antigen vaccines and compositions against streptococcus pneumoniae |
CA2900008A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
WO2018183475A1 (en) | 2017-03-28 | 2018-10-04 | Children's Medical Center Corporation | A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof |
BR112021004193A2 (pt) | 2018-09-12 | 2021-05-25 | Affinivax, Inc. | vacinas pneumocócicas multivalentes |
-
2012
- 2012-05-11 KR KR1020137032789A patent/KR20140146993A/ko active Search and Examination
- 2012-05-11 RU RU2013154706A patent/RU2632651C2/ru active
- 2012-05-11 CA CA2835628A patent/CA2835628C/en active Active
- 2012-05-11 ES ES12782582T patent/ES2864765T3/es active Active
- 2012-05-11 EP EP21156431.5A patent/EP3881836A1/en active Pending
- 2012-05-11 CN CN201280034719.6A patent/CN103732222B/zh active Active
- 2012-05-11 JP JP2014510498A patent/JP6366501B2/ja active Active
- 2012-05-11 EP EP12782582.6A patent/EP2709603B1/en active Active
- 2012-05-11 RU RU2013154489A patent/RU2619176C2/ru active
- 2012-05-11 WO PCT/US2012/037412 patent/WO2012155007A1/en active Application Filing
- 2012-05-11 MX MX2013013111A patent/MX2013013111A/es unknown
- 2012-05-11 MX MX2013013112A patent/MX2013013112A/es unknown
- 2012-05-11 CA CA2835630A patent/CA2835630A1/en active Pending
- 2012-05-11 US US14/116,402 patent/US10766932B2/en active Active
- 2012-05-11 CN CN201280034406.0A patent/CN103648489A/zh active Pending
- 2012-05-11 WO PCT/US2012/037541 patent/WO2012155053A1/en active Application Filing
- 2012-05-11 CN CN201810398905.7A patent/CN108714212A/zh active Pending
- 2012-05-11 CN CN201810413217.3A patent/CN108840912B/zh active Active
- 2012-05-11 BR BR112013028892-2A patent/BR112013028892B1/pt active IP Right Grant
- 2012-05-11 JP JP2014510481A patent/JP6152378B2/ja active Active
- 2012-05-11 KR KR1020137032751A patent/KR102084509B1/ko active IP Right Grant
- 2012-05-11 EP EP21156712.8A patent/EP3912619A1/en active Pending
- 2012-05-11 KR KR1020217009127A patent/KR102494245B1/ko active IP Right Grant
- 2012-05-11 KR KR1020197025288A patent/KR102234933B1/ko active IP Right Grant
- 2012-05-11 BR BR112013028887-6A patent/BR112013028887B1/pt active IP Right Grant
- 2012-05-11 US US14/116,492 patent/US9499593B2/en active Active
- 2012-05-11 AU AU2012253327A patent/AU2012253327B2/en active Active
- 2012-05-11 AU AU2012253359A patent/AU2012253359B2/en active Active
- 2012-05-11 EP EP12781636.1A patent/EP2706991B1/en active Active
- 2012-05-11 ES ES12781636T patent/ES2864764T3/es active Active
-
2013
- 2013-11-11 ZA ZA2013/08461A patent/ZA201308461B/en unknown
- 2013-11-11 ZA ZA2013/08465A patent/ZA201308465B/en unknown
-
2015
- 2015-11-19 US US14/946,372 patent/US10017548B2/en active Active
-
2017
- 2017-05-29 JP JP2017105191A patent/JP6502420B2/ja active Active
-
2018
- 2018-05-30 US US15/992,343 patent/US10611805B2/en active Active
- 2018-07-03 JP JP2018126516A patent/JP6666389B2/ja active Active
-
2019
- 2019-03-20 JP JP2019052175A patent/JP2019104758A/ja active Pending
-
2020
- 2020-02-10 US US16/785,937 patent/US11560410B2/en active Active
- 2020-02-20 JP JP2020026905A patent/JP7336402B2/ja active Active
- 2020-07-31 US US16/945,714 patent/US20210332090A1/en active Pending
-
2022
- 2022-10-13 US US18/046,485 patent/US20240025952A1/en active Pending
-
2023
- 2023-08-21 JP JP2023133790A patent/JP2023162283A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013013111A (es) | Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma. | |
MX363307B (es) | Plataformas para suministro de antigenos. | |
TN2015000247A1 (en) | Bcma antigen binding proteins | |
MY173004A (en) | Mycobacterial antigen vaccine | |
EA035991B9 (ru) | Новый полисахарид и его применения | |
MX342034B (es) | Proteinas monovalentes que se unen a antigenos. | |
TN2014000120A1 (en) | Cd27l antigen binding proteins | |
MX354924B (es) | Molecula portadora que comprende un antigeno spr0096 y un spr2021. | |
WO2012027365A3 (en) | Targeted multi-epitope dosage forms for induction of an immune response to antigens | |
EP4056198A3 (en) | Outer membrane vesicles | |
WO2013054199A3 (en) | Cmv antigens and uses thereof | |
MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
PH12015501101B1 (en) | Method for eliciting an immune response to an immunogen | |
WO2014136064A3 (en) | Immunogenic fusion polypeptides | |
WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
WO2012064792A3 (en) | Protein complexes for antigen binding and methods of use | |
MX2017001638A (es) | Molecula portadora para antigenos. | |
NZ603863A (en) | Concentration and lyophilization of influenza vaccine antigens | |
IN2014DN09791A (es) | ||
MX2015002482A (es) | Composicion inmunogenica. | |
MX2014006630A (es) | Vacuna a base toxina clostridium difficile. | |
MX349657B (es) | Composiciones de vacuna de matriz de proteína que incluyen policationes. | |
EP2762153A3 (en) | Vaccine composition for mucosal administration | |
MX2017008406A (es) | Conjugados de aminoacidos y peptidos y sus usos. | |
MX2014001626A (es) | Preservacion asistida con vacio de productos biologicos, en particular de vacunas. |